CASTOR Trial: Daratumumab Combination Doubles Response Rates in Myeloma Patients

Antonio Palumbo, MD, discusses the “unprecedented” results of the CASTOR Trial, a plenary, late-breaking abstract at ASCO 2016.

SHARE